In a murine breast cancer model, nanocomplexes releasing pro-apoptotic peptides in response to tumour-associated cathepsin B significantly improved the efficacy of doxorubicin, reducing tumour growth by up to 91% [53]. The gene discussed is CTSB; the disease is breast carcinoma.